drug-induced dyskinesia
drug-induced dyskinesia
Explore linked clinical trials. Standard reference: MONDO:000673210 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | Bipolar and Related Disorders, Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Signs and Symptoms, bipolar disorder, central nervous system disorder, depressive disorder, drug-induced dyskinesia, major depressive disorder, mood disorder, movement disorder, nervous system disorder, psychiatric disorder, schizoaffective disorder, schizophrenia, tardive dyskinesia | Recruiting | Phase 4 | 2026-09-18 | NCT07105111 | |
| rTMS as an Intervention for Levodopa-induced Dyskinesia | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Dyskinesias, Neurologic Manifestations, Nutritional and Metabolic Diseases, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, drug-induced dyskinesia, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, poisoning, proteostasis deficiencies, synucleinopathy, toxic encephalopathy | Recruiting | Not applicable | 2026-08-27 | NCT06570824 | |
| A Computer-Assisted Tool for Objective Assessment of Extrapyramidal Symptoms | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Signs and Symptoms, central nervous system disorder, drug-induced akathisia, drug-induced dyskinesia, movement disorder, nervous system disorder, poisoning, tardive dyskinesia, toxic encephalopathy | Not yet recruiting | Not stated | 2026-07-21 | NCT07715994 | |
| Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities | Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system disorder, developmental disability, drug-induced dyskinesia, intellectual disability, movement disorder, nervous system disorder, neurodevelopmental disorder, psychiatric disorder, tardive dyskinesia | Recruiting | Phase 4 | 2026-07-06 | NCT06997198 | |
| Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system disorder, drug-induced dyskinesia, movement disorder, nervous system disorder, tardive dyskinesia | Recruiting | Phase 2 | 2026-06-23 | NCT07365462 | |
| Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system disorder, drug-induced dyskinesia, movement disorder, nervous system disorder, tardive dyskinesia | Recruiting | Not applicable | 2025-12-05 | NCT07173920 | |
| ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Dyskinesias, Huntington disease, Neurologic Manifestations, Nutritional and Metabolic Diseases, Orofacial Dyskinesia, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Wilson disease, atactic disorder, non-human animal, basal ganglia disorder, brain disorder, central nervous system disorder, choreatic disease, cognitive disorder, dementia, drug-induced dyskinesia, dystonic disorder, essential tremor, hereditary disease, inborn errors of metabolism, inborn metal metabolism disorder, inherited neurodegenerative disorder, liver disorder, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, psychiatric disorder, synucleinopathy, tardive dyskinesia | Active, not recruiting | Not applicable | 2025-05-01 | NCT02252380 | |
| Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system disorder, drug-induced dyskinesia, movement disorder, nervous system disorder, tardive dyskinesia | Recruiting | Phase 1 / Phase 2 | 2025-01-22 | NCT06731868 | |
| Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system disorder, drug-induced dyskinesia, movement disorder, nervous system disorder, tardive dyskinesia | Not yet recruiting | Not stated | 2024-01-23 | NCT06218719 | |
| Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, drug-induced dyskinesia, movement disorder, nervous system disorder, parkinsonian disorder, psychiatric disorder, schizoaffective disorder, schizophrenia, tardive dyskinesia | Recruiting | Phase 4 | 2019-03-22 | NCT03495024 |